CJC-1295 Ipamorelin Peptide Blend

Both levers of the growth hormone axis in one vial, on a theory.

CJC-1295 ipamorelin is a blend of two compounds that act at different receptors on the same axis: CJC-1295, a 30-residue analogue of growth hormone releasing factor hGRF(1-29) carrying four substitutions that resist degradation, and ipamorelin, a pentapeptide agonist at the growth hormone secretagogue receptor. Both are named on the WADA Prohibited List under section S2, CJC-1295 among GHRH analogues and ipamorelin among growth hormone secretagogues.

The growth hormone axis has two control levers, and this blend pulls both at once.

Lever one: the GHRH receptor. That's the CJC-1295 half, a stabilised analogue of the natural releasing hormone.

The rationale is textbook physiology. The two receptors are separate inputs to the same somatotroph cells, and your body already uses them together, on its own, without anybody's help.

So combining them isn't a random stack. It's an imitation of an arrangement that already exists. The doorbell and the knock, at the same door, at the same time.

We sell it by the vial, and the box of ten knocks 25% off.

A sensible theory in a vial. The word doing all the work in that sentence is theory.

The physiology says the levers are synergistic. The literature has not checked this pairing.

The doorbell and the knock. Same door. That's the design.

The GHRH arm asks through its receptor. The ipamorelin arm asks through the ghrelin receptor, and asks unusually cleanly, without the cortisol spillover of its older siblings.

What isn't established is this specific pairing at this specific ratio, because nobody's run that study. Not once.

And blends carry a permanent reading problem. Whatever result you get, you can't hand it to either component. It's like your buddy ordering the two-for-one combo and then reviewing it as a single dish.

Here's the honest part. Real physiology underneath, real components each with a real file, and a combination that exists commercially rather than scientifically.

The blend is plausible. Plausible is a starting line, not a finding.

Each component has its own file. The combination has approximately none.

Read this file as three files, because that's what it is.

CJC-1295 alone: real pharmacokinetic work, including the DAC half-life data.

Ipamorelin alone: a genuinely clean selectivity profile, documented by Novo Nordisk in the nineties.

That's the standard blend problem, and it's on every combo page on the internet: component evidence gets borrowed, dressed up as combination evidence, and handed to you as if somebody had tested the mix. The only way you'd ever know is to check what was actually studied.

Nothing approved, individually or together. Prohibited in sport.

Two respectable files and an empty one, sold as a set. Check which file any claim you read is actually citing.

Know which CJC-1295 you have. With DAC and without DAC are different molecules, differing by about 279 daltons and by roughly a hundredfold in duration. FDA has flagged that common names make it impossible to know which structure is intended. A measured mass is the only way to tell them apart.

Same day out of British Columbia. Our building, our cold packs, our people, and nothing sitting in a customs queue while you refresh a tracking page.

Both components are named on the WADA list. Section S2.2.4 of the 2026 Prohibited List names CJC-1295 among GHRH analogues and ipamorelin among growth hormone secretagogues. Both prohibited at all times, in and out of competition, and non-specified.